Showing results (1851-1860 of 2,010) with videos related to

Sort By:
Pageof 201
Blood|March 15, 2014
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasmsSa A Wang, Robert P Hasserjian, Patricia S Fox, et al.
Radiology|July 22, 2016
Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y RadioembolizationKazim H Narsinh, Mark Van Buskirk, Andrew S Kennedy, et al.
Emerging Microbes & Infections|January 20, 2022
B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responsesKe Lin, Yawen Zhou, Jingwen Ai, et al.
Haematologica|December 24, 2025
Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s)Sa A Wang, Chi Young Ok, Harrison K Tsai, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Loss of tight junction protein claudin 18 uncovers alveolar epithelial stem cell plasticity and emergence of non-fibrogenic transitional progenitorsA Castaldi, J S Chin, B Ma, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 17, 2017
Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial controlYi An, Wen Jiang, Betty Y S Kim, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 14, 2021
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology GroupRashmi Kanagal-Shamanna, Attilio Orazi, Robert P Hasserjian, et al.
JCO Precision Oncology|December 10, 2025
Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute LeukemiaHannah Goulart, Farhad Ravandi, Nicholas J Short, et al.
Neuropharmacology|May 31, 2011
The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodentsP H Hutson, E N Finger, B C Magliaro, et al.
Leukemia|July 21, 2025
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapyAlexandre Bazinet, Sanam Loghavi, Yue Wei, et al.
Pageof 201